secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2026-07-13T11:09:59+00:00
Accession:  0001193125-26-301464
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio: positive 36-week Phase 2a data for bempikibart in alopecia areata; registration trial planned H1 2027
--------------------------------------------------------------------------------

- Mean percent reduction in SALT score from baseline of 35.3% in mITT analysis at Week 36.
- 40% (10/25) mITT and 30.3% (10/33) ITT achieved SALT-20; 44% achieved SALT-30 and SALT-50.
- No serious adverse events or Grade 3+ treatment-related AEs; mild injection site reaction in 36.3% of patients (4% of doses).
- Company paid off remaining $6.8M loan to Silicon Valley Bank on June 24, 2026; loan agreement terminated.
- Plans to advance bempikibart into registration-directed program in first half of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526301464/0001193125-26-301464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526301464/d142528d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-301464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer